...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs and aging >Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data
【24h】

Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data

机译：澳大利亚较旧的葡萄糖药物的分配和成本的趋势：国家索赔数据的调查结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Temporal changes in the dispensing of glucose-lowering drugs (GLD) and their associated costs among elderly populations is unclear. This information is especially relevant to countries in which medications are partly or fully government subsidized. Objective Our objective was to estimate the trends in prevalence, incidence and costs associated with GLD dispensed to older Australians. Methods We analysed Pharmaceutical Benefits Scheme data for 76,906 people aged >= 65 years dispensed diabetes medications over the period 2013-2016. Results Older males were dispensed more GLD than were older females, with the marginal difference increasing from 3.2% in 2013 (age-sex adjusted incidence rate ratio [aIRR] 1.032; 95% confidence interval [CI] 1.024-1.041; p = 75 years than in those aged 65-74 years, with the gap widening over the years. More patients were initiated with sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors over the study period, at the expense of older GLD. The proportion of users and attributed costs associated with the use of metformin, sulfonylureas, alpha-glucosidase inhibitors and thiazolidinediones decreased over time. The total subsidized costs of GLD is forecast to increase to $A395 million by 2020. Conclusions The treatment landscape for diabetes in Australia is undergoing dynamic change. More patients were initiated with the newer but costlier GLD over the study period.
机译：背景技术降低葡萄糖药物（GLD）分配的时间变化及其在老年人口中的相关成本尚不清楚。该信息与药物部分或完全政府补贴的国家特别相关。目的是我们的目标是估计与澳大利亚较旧的GLD相关的患病率，发病率和成本的趋势。方法分析了76,906人> = 65岁的药物益处计划数据在2013 - 2016年期间分配了76,906人的糖尿病药物。结果较旧的男性比年龄较大的女性分配更多的GLD，从2013年的3.2％增加了边际差异（年龄 - 性调整后发病率比[AIRR] 1.032; 95％置信区间[CI] 1.024-1.041; P = 75岁比在65-74岁的年龄段，多年来差距扩大了。更多患者用钠葡萄糖COT转换器-2抑制剂，胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂在研究期间开始，在研究期间较旧的GLD费用。随着时间的推移，使用二甲双胍，磺脲类，α-葡糖苷酶抑制剂和噻唑烷基的使用比例和归属于使用二甲双胍，硫酸脲，α-葡糖苷酶抑制剂的比例。预计GLD的总补贴成本将增加到2020年的增加至39.5百万美元。结论澳大利亚糖尿病的治疗景观正在进行动态变化。在研究期间，更多患者与较新但Costlier GLD发起。

著录项

  • 来源
    《Drugs and aging》 |2020年第5期|共6页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号